These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16631267)

  • 21. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
    Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW
    Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
    Weckermann D; Dorn R; Trefz M; Wagner T; Wawroschek F; Harzmann R
    J Urol; 2007 Mar; 177(3):916-20. PubMed ID: 17296375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.
    Pommier P; Chabaud S; Lagrange JL; Richaud P; Lesaunier F; Le Prise E; Wagner JP; Hay MH; Beckendorf V; Suchaud JP; Pabot du Chatelard PM; Bernier V; Voirin N; Perol D; Carrie C
    J Clin Oncol; 2007 Dec; 25(34):5366-73. PubMed ID: 18048817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of common iliac nodal treatment on radiation outcomes in localized prostate cancer.
    Soto DE; Glaser S; Roberts RH; Schipper MJ; McLaughlin PW; Ray ME; Sandler HM; Pan CC
    Urology; 2008 Feb; 71(2):313-7. PubMed ID: 18308110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low pre-radiotherapy prostate-specific antigen level is a significant predictor of treatment success for postoperative radiotherapy in patients with prostate cancer.
    Sasaki T; Nakamura K; Shioyama Y; Ohga S; Toba T; Urashima Y; Yoshitake T; Terashima H; Koga H; Naito S; Noma H; Komatsu K; Yamaguchi A; Hiratsuka Y; Hirano T; Hanada K; Abe M; Fujisawa Y; Honda H
    Anticancer Res; 2006; 26(3B):2367-74. PubMed ID: 16821618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers.
    Boorjian SA; Karnes RJ; Rangel LJ; Bergstralh EJ; Frank I; Blute ML
    BJU Int; 2008 Feb; 101(3):299-304. PubMed ID: 17922854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.
    Yamazaki H; Nishiyama K; Tanaka E; Maeda O; Meguro N; Kinouchi T; Usami M; Kakimoto K; Ono Y; Nishimura T
    Anticancer Res; 2008; 28(6B):3913-20. PubMed ID: 19192649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer.
    Jereczek-Fossa BA; Orecchia R
    Radiother Oncol; 2007 Aug; 84(2):197-215. PubMed ID: 17532494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changing patterns of pelvic lymphadenectomy for prostate cancer: results from CaPSURE.
    Kawakami J; Meng MV; Sadetsky N; Latini DM; Duchane J; Carroll PR;
    J Urol; 2006 Oct; 176(4 Pt 1):1382-6. PubMed ID: 16952638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer.
    Wyler SF; Sulser T; Seifert HH; Ruszat R; Forster TH; Gasser TC; Bachmann A
    Urology; 2006 Oct; 68(4):883-7. PubMed ID: 17070376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer.
    Zelefsky MJ; Yamada Y; Kollmeier MA; Shippy AM; Nedelka MA
    Eur Urol; 2008 Jun; 53(6):1172-9. PubMed ID: 18222596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.
    Ganswindt U; Paulsen F; Corvin S; Hundt I; Alber M; Frey B; Stenzl A; Bares R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):347-55. PubMed ID: 17236960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years.
    Schostak M; Krause H; Miller K; Schrader M; Kempkensteffen C; Kollermann J
    BJU Int; 2007 Jun; 99(6):1409-14. PubMed ID: 17428244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences.
    Muren LP; Wasbø E; Helle SI; Hysing LB; Karlsdottir A; Odland OH; Valen H; Ekerold R; Johannessen DC
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1034-41. PubMed ID: 18249502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.